Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Age Gard TX
- Development stage
- Phase 3
- Lead developer
- VTS Life Sciences
- Modality
- Small Molecules, Peptides
- Administration
- Oral
01
Overview
**Age Gard TX** is a VTS Life Sciences-marketed oral fixed-dose tablet formulation listed in the company’s product catalogue. A product listing identifies the active ingredients as tranexamic acid and glutathione. Tranexamic acid is an antifibrinolytic lysine analogue that reversibly occupies lysine-binding sites on plasminogen, limiting plasmin generation; its dermatologic use for pigmentary disorders is distinct from its hemostatic pharmacology. The exact dose strengths, regulatory status, manufacturing site, and indication for the non-Forte Age Gard TX product were not stated in the primary company catalogue. ([vtslifesciences.in](https://vtslifesciences.in/products.html))
- Brand names
- Age Gard TX
02
Targets
PLG (Plasminogen)TYR (Tyrosinase)
Beyond the preview
Go deeper on Age Gard TX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Age Gard TX.